



## ABSORPTION CORRECTION METHOD FOR THE SIMULTANEOUS ESTIMATION OF AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE IN BULK AND IN COMBINED TABLET DOSAGE FORM

ANANDAKUMAR K.\* AND JAYAMARIAPPAN M.

Department of Pharmaceutical Analysis, Adhiparasakthi College of Pharmacy, Melmaruvathur - 603 319 Tamil Nadu, India  
Email: anandkarunakaran@gmail.com

Received: 20 May 2010, Revised and Accepted: 23 Oct 2010

### ABSTRACT

A new, simple, accurate and sensitive UV - spectrophotometric absorption correction method has been developed for simultaneous determination of amlodipine besylate, valsartan and hydrochlorothiazide in bulk and in combined tablet dosage form. Methanol and distilled water were used as solvents. The wavelengths selected for the analysis were 365 nm, 250 nm and 315 nm for amlodipine besylate, valsartan and hydrochlorothiazide, respectively. Beer's law obeyed the concentration range of 1 - 32 µg/ ml, 4 - 40 µg/ ml and 2 - 20 µg/ ml for amlodipine besylate, valsartan and hydrochlorothiazide, respectively. The percentage recovery was found in the range of 100.42 - 101.27% for amlodipine besylate, 100.51 - 101.40% for valsartan and 99.25 - 100.35% for hydrochlorothiazide. The developed method was validated statistically and by recovery studies. The % RSD value was found to be less than 2. Thus the proposed method was simple, precise, economic, rapid and accurate and can be successfully applied for simultaneous determination of amlodipine besylate, valsartan and hydrochlorothiazide in bulk and in combined tablet dosage form.

**Keywords:** Amlodipine Besylate, Valsartan, hydrochlorothiazide, Absorption correction method, ICH guidelines.

### INTRODUCTION

Amlodipine besylate (AMB), 2 - [(2 - amino ethoxy) - methyl] - 4 - (2 - chloro phenyl) - 1, 4 - dihydro - 6 - methyl - 3, 5 - pyridine dicarboxylic acid 3 - ethyl - 5 - methyl ester, benzene sulfonate (Fig. 1), is a potent dihydro calcium channel blocker<sup>1</sup>. Various analytical methods have been reported for the assay of AMB alone or in combination with other anti - hypertensive agents in pharmaceutical formulations. They include UV spectroscopy<sup>2-4</sup>, high performance liquid chromatography<sup>5-8</sup>, high performance thin layer chromatography<sup>9, 10</sup>, LC - MS<sup>11</sup> and LC - MS/ MS<sup>12</sup>.




Fig. 1: Chemical structure of Amlodipine besylate.

Valsartan (VAL) chemically, N - (1 - oxopentyl) - N - [(2' - (1H - tetrazol - 5 - yl) (1, 1' - biphenyl) - 4 - yl) methyl] - L - valine (Fig. 2), is a potent angiotensin receptor blocker<sup>13, 14</sup>. Methods such as HPLC<sup>15-17</sup>, LC - MS<sup>18-20</sup>, in plasma<sup>21</sup>, Capillary electrophoresis<sup>22</sup> and simultaneous UV spectrophotometric methods<sup>23, 24</sup> are reported for estimation of VAL alone or in combination with other drugs.




Fig. 2: Chemical structure of Valsartan.

Hydrochlorothiazide (HCT), 6 - chloro - 3, 4 - dihydro - 7 - sulfamoyl - 2H - 1, 2, 4 - benzothia - diazine - 1, 1 - dioxide (Fig. 3), is a thiazide diuretic<sup>25</sup>. It increases sodium and chloride excretion in distilled convoluted tubule. Many analytical methods for HCT alone or in combination with other drugs including spectroscopic and chromatographic methods are also reported in literature<sup>26 - 31</sup>.




Fig. 3: Chemical structure of Hydrochlorothiazide.

All the three drugs are official in USP<sup>32</sup>. Amlodipine besylate and Hydrochlorothiazide are official in IP<sup>33</sup> and BP<sup>34</sup>.

Literature survey revealed that there are several methods were reported for the estimation of AMB, VAL and HCT individually as well as in combination with some other drugs. As no method is reported for AMB, VAL and HCT in combination, the aim of the present study was to develop accurate, precise and sensitive method for the simultaneous UV spectrophotometric estimation of AMB, VAL and HCT in bulk and in combined tablet dosage form by absorption correction method. For this purpose marketed tablets Exforge HCT containing 10 mg of AMB, 160 mg of VAL and 25 mg of HCT was used.

### MATERIALS AND METHODS

#### Instrumentation

The present work was carried out on Shimadzu - 1700 double beam UV - Visible spectrophotometer with pair of 10 mm matched quartz cells. Glassware's used were of 'A' grade and were soaked overnight in a mixture of chromic acid and sulphuric acid, rinsed thoroughly with double distilled water and dried in hot air oven.

#### Reagent and chemicals

Pharmaceutically pure sample of AMB, VAL and HCT were obtained as a gift samples from Caplin point, Chennai. All solvents were of AR grade obtained from Qualigens India Pvt. Limited, Mumbai. A

combination of AMB (10 mg), VAL (160 mg) and HCT (25 mg) in tablet formulation was procured from U.S market (Exforge HCT, Novartis pharmaceutical corporation, Switzerland).

### Experimental condition

According to the solubility characteristics, the common solvent for the three drugs was found to be methanol. Hence the stock solution was prepared in methanol and further dilutions were made up with distilled water.

### Preparation of standard stock solution

50 mg of AMB, 40 mg of VAL and 20 mg of HCT were accurately weighed and transferred in to 50 ml volumetric flasks separately. Dissolved in methanol and made up to the volume to 50 ml with the same. These solutions were observed to contain 1000 µg/ ml, 800 µg/ ml and 400 µg/ ml of AMB, VAL and HCT, respectively.

### Study of spectral and linearity characteristics

The standard stock solutions of AMB, VAL and HCT were further diluted with distilled water to get the concentration of 10 µg/ ml of each and the solutions were scanned between the range 200 - 400 nm in 1cm cell against distilled water as blank and the overlain spectra was recorded.

From the overlain spectrum of AMB, VAL and HCT in methanol followed by distilled water, it was observed that VAL and HCT have zero absorbance at 365 nm, where as AMB has substantial absorbance. Thus AMB was estimated directly at 365 nm without interference of VAL and HCT. At 315 nm, VAL has zero absorbance. For estimation of HCT, the absorbance of AMB was measured at 315 nm using standard solution of AMB (10 µg/ ml). The contribution of AMB was deducted from the total absorbance of sample mixture at 315 nm. The calculated absorbance was called as corrected absorbance for HCT. At 250 nm, these three drugs were showed the absorbance. To estimate the amount of VAL, the absorbance of AMB and HCT were corrected for interference at 250 nm by using absorptivity values. A set of three equations were framed using absorptivity coefficients at selected wavelengths.

$$C_x = \frac{A_1}{a_{x1}}$$

$$C_y = \frac{A_2 - a_{x2} C_x}{a_{y2}}$$

$$C_z = \frac{A_3 - (a_{x2} C_x + a_{y3} C_y)}{a_{z3}}$$

Where,

$A_1$ ,  $A_2$  and  $A_3$  are absorbance of sample solution at 365 nm, 315 nm and 250 nm, respectively.

$a_{x1}$ ,  $a_{x2}$  and  $a_{x3}$ , absorptivity coefficients of AMB at 365 nm, 315 nm and 250 nm, respectively.

$a_{y2}$  and  $a_{y3}$ , absorptivity coefficients of HCT at 315 nm and 250 nm, respectively.

$a_{z3}$ , absorptivity coefficient of VAL at 250 nm.

$C_x$ ,  $C_y$  and  $C_z$  are concentrations of AMB, VAL and HCT, respectively in mixture.

The aliquot portions of standard stock solution of AMB, VAL and HCT were transferred into 100 ml volumetric flasks individually and made up to the volume with distilled water. The absorbance of different concentration solutions were measured at 365 nm, 315 nm and 250 nm for AMB, 315 nm and 250 nm for HCT and 250 nm for VAL. The calibration curves for AMB, VAL and HCT were prepared in the concentration range of 1 - 32 µg/ ml, 4 - 40 µg/ ml and 2 - 20 µg/ ml, respectively at their respective wavelengths by diluting aliquot portions of standard stock solution of each drug.

### Analysis of synthetic mixture of AMB, VAL and HCT

Different mixtures of the three drugs were prepared by transferring different volumes of AMB, VAL and HCT from standard stock solutions into 100 ml volumetric flasks and diluting to volume with distilled water. The concentrations of all the three drugs AMB, VAL and HCT were determined by measuring the absorbance of the prepared mixtures at 365 nm, 315 nm and 250 nm. From these absorbance values, the concentrations of AMB, VAL and HCT were determined using absorbance correction method.

### Analysis of tablet formulation

Twenty tablets were weighed and average weight was found. The tablets were triturated to a fine powder. An accurately weighed quantity of powder equivalent to 40 mg of VAL was transferred in to 50 ml volumetric flask and added a minimum quantity of methanol to dissolve the substance and made up to the volume with the same. The solution was sonicated for 15 minutes, centrifuged for another 15 minutes at 100 rpm and filtered through Whatmann filter paper No. 41. From the clear solution, further dilutions were made by diluting 4.0 ml into 100 ml with distilled water to obtain 32 µg/ ml solution of VAL which is also contains 2 µg/ ml of AMB and 5 µg/ ml of HCT theoretically. The absorbance of sample solution was measured at all selected wavelengths. The content of AMB, VAL and HCT in sample solution of tablet was calculated. This procedure was repeated for six times.

### Validation of methods

The methods were validated with respects to linearity, LOD (Limit of detection), LOQ (Limit of quantitation), precision, accuracy and ruggedness<sup>35</sup>.

### Linearity

Linearity was checked by diluting standard stock solution at six different concentrations. AMB was linear with the concentration range of 1 - 32 µg/ ml at 365 nm, 315 nm and 250 nm. VAL showed the linearity in the range of 4 - 40 µg/ ml at 250 nm. HCT was linear in the concentration range of 2 - 20 µg/ ml at 315 nm and 250 nm and Calibration curves ( $n = 6$ ) were plotted between concentration and absorbance of drugs. Optical parameters were calculated.

### Sensitivity

The limit of detection (LOD) and limit of quantitation (LOQ) parameters were calculated using the following equations;  $LOD = 3.3\sigma / s$  and  $LOQ = 10\sigma / s$ , where  $\sigma$  is standard deviation of y intercept of calibration curve ( $n = 6$ ) and  $s$  is slope of regression equation.

### Precision

The precision of the method was confirmed by repeatability and intermediate precision. The repeatability was performed by the analysis of formulation was repeated for six times with the same concentration. The amount of each drug present in the tablet formulation was calculated. The % RSD was calculated. The intermediate precision of the method was confirmed by intraday and inter day analysis i.e. the analysis of formulation was repeated three times in the same day and on three successive days. The amount of drugs was determined and % RSD also calculated.

### Accuracy

To check the accuracy of the developed method and to study the interference of formulation excipients, analytical recovery experiments were carried out by using standard addition method in three different concentrations. From the total amount of drug found, the percentage recovery was calculated. This procedure was repeated for three times for each concentration. The % RSD was calculated.

### Ruggedness

The ruggedness test of analytical assay method is defined as the degree of reproducibility of test results obtained by the analysis of the same samples under a variety of normal test conditions such as different labs, different analysis, different lots of reagents etc. Ruggedness is a measure of reproducibility of test results under normal expected operational conditions from laboratory to laboratory and from analyst to analyst. In present study, determination of AMB, VAL and HCT were carried out by using different instruments and different analysts.

### RESULTS AND DISCUSSION

An attempt has been made to develop a rapid, sensitive, economic, precise and accurate analytical method for simultaneous estimation of AMB, VAL and HCT in pure and in combined tablet dosage form. The proposed method is based on spectrophotometric absorption correction method for the simultaneous estimation of AMB, VAL and HCT in UV region using methanol and distilled water as solvents. The overlain spectra of AMB, VAL and HCT are shown in Fig. 4.

The method is based upon direct estimation of AMB at 365 nm, as at this wavelength HCT and VAL have zero absorbance and shows no interference. For estimation of HCT, corrected absorbance was calculated at 315 nm due to the interference of AMB and VAL has zero absorbance at this wavelength. At 250 nm, these three drugs were showed absorbance. To estimate the amount of VAL, the absorbance of AMB and HCT were corrected for interference at 250 nm by using their absorptivity values. The stability was performed by measuring the absorbance of same solution at different time intervals. It was observed that AMB, VAL and HCT were stable for up to 4 hours at their respective wavelengths.

Beer's law obeyed in the concentration range of 1 - 32 µg/ ml at 365 nm, 315 nm and 250 nm, 4 - 40 µg/ ml at 250 nm and 2 - 20 µg/ ml at 315 nm and 250 nm for AMB, VAL and HCT, respectively. The correlation coefficient values were found above 0.999, which shows that absorbance of all the drugs was linear with concentration. The optical characteristics such as Beer's law limits, correlation coefficient, slope, intercept, Sandell's sensitivity and molar absorptivity were calculated and are summarized in Table 1.




Fig. 4: Overlain UV spectra of AMB, VAL and HCT (10 µg/ ml)

Table 1: Spectral and linearity characteristics data.

Parameters	AMB*	VAL*	HCT*
$\lambda_{max}$ (nm)	365 nm	250 nm	315 nm
Linearity range (µg/ ml)	1 - 32	4 - 40	2 - 20
Correlation coefficient ( $r^2$ )	0.99990	0.99971	0.99985
Molar absorptivity ( $L \text{ mol}^{-1} \text{ cm}^{-1}$ )	6807.54	14086.53	3325.88
Sandell's sensitivity ( $\mu\text{g}/\text{cm}^2/0.001 \text{ A.U}$ )	0.060549	0.030528	0.089152
Slope (m)	0.016511	0.03276	0.011226
Intercept (c)	0.001330	0.004158	0.000556
Regression equation ( $y = mx + c$ )	$y = 0.016511x + 0.001330$	$y = 0.03276x + 0.004158$	$y = 0.011226x + 0.000556$
LOD (µg/ ml)	0.1798	0.2953	0.2460
LOQ (µg/ ml)	0.5451	0.8949	0.7467
Standard Error	0.000409	0.002055	0.000252

\* Mean of six observations.

The LOD and LOQ were found to be 0.1798 and 0.5451, 0.2953 and 0.8949, 0.2460 and 0.7467 for AMB, VAL and HCT, respectively. The low values indicated that the sensitivity of the method.

To study the mutual interference, if any, in the simultaneous estimation of AMB, VAL and HCT in synthetic mixture containing various proportions of AMB, VAL and HCT were prepared and the contents were estimated by proposed method. The % recovery varied from 99.59 to 101.12 for AMB, 99.78 to 101.22 for VAL and 99.69 to 101.85 for HCT indicating that there is no mutual interference between these three drugs. The result of analysis of synthetic mixture is shown in Table 2.

The percentage label claim present in tablet formulation was found to be  $99.36 \pm 1.9111$ ,  $99.53 \pm 0.3543$ ,  $101.72 \pm 1.3547$  for AMB, VAL and HCT, respectively. Precision of the method was confirmed by the repeated analysis of formulation for six times. The % RSD values

were found to be 1.9234, 0.3559 and 1.3318 for AMB, VAL and HCT, respectively. The low % RSD values indicated that all the three drugs showed good agreement with the label claim ensures the precision of the method (Table 3).

Further, the precision of the method was confirmed by Intraday and Inter day analysis. The % RSD values for intraday and inter day analysis was found to be 0.4078 and 1.5058 for AMB, 0.1140 and 0.3459 for VAL and 0.5056 and 1.7086 for HCT, respectively. Hence the precision of the method was further confirmed.

The developed method was validated for Ruggedness. The analysis of formulation was done by using different instruments and different analysts. The % RSD values were found to be less than 2 indicating that the method was more rugged. The results of analysis of intermediate precision and ruggedness are shown in Table 4.

Table 2: Results of analysis of synthetic mixtures

Conc. of AMB ( $\mu\text{g/ml}$ )			Conc. of VAL ( $\mu\text{g/ml}$ )			Conc. of HCT ( $\mu\text{g/ml}$ )		
Theoretical	Experimental	% recovery	Theoretical	Experimental	% recovery	Theoretical	Experimental	% recovery
1	1.0112	101.12	16	15.9648	99.78	2.5	2.5463	101.85
2	2.0134	100.67	18	17.9832	99.91	5	4.9843	99.69
3	2.9876	99.59	20	20.0190	100.10	7.5	7.5219	100.29
4	3.9945	99.86	22	22.0467	100.21	10	9.9757	99.76
5	5.0189	100.38	24	24.2938	101.22	12.5	12.5631	100.50

Table 3: Results of analysis of tablet formulation

Parameters	AMB	VAL	HCT
Labeled	10	160	25
Claim (mg)	99.36	99.53	101.72
% Assay*	1.9111	0.3543	1.3547
SD	1.9234	0.3559	1.3318
% RSD			

\* Mean of six determinations.

Table 4: Intermediate Precision and Ruggedness of the method

Parameters	% Label claim estimated (Mean $\pm$ %R.S.D.)		
	AMB	VAL	HCT
Intraday Precision (n=3)	101.60 $\pm$ 0.4078	99.62 $\pm$ 0.1140	102.22 $\pm$ 0.5056
Inter day Precision (n=3)	101.03 $\pm$ 1.5058	99.31 $\pm$ 0.3459	100.73 $\pm$ 1.7086
Different instruments (n=6)			
Instrument I	100.74 $\pm$ 1.7280	101.12 $\pm$ 1.8160	99.26 $\pm$ 0.1792
Instrument II	99.58 $\pm$ 0.6867	99.81 $\pm$ 0.1161	102.36 $\pm$ 1.5743
Different analysts (n=6)			
Analyst I	98.15 $\pm$ 0.7864	102.32 $\pm$ 0.3606	99.80 $\pm$ 0.2469
Analyst II	101.47 $\pm$ 1.3209	99.31 $\pm$ 0.3130	101.88 $\pm$ 0.4397

In order to check the accuracy of the developed method, known quantities of standard drugs of AMB, VAL and HCT in three different concentrations were added to its preanalysed sample and analysed by the developed method. The percentage recovery was found to be in the range of 100.42 - 101.27% for AMB, 100.51 - 101.40% for VAL

and 99.25 - 100.35% for HCT. The results of recovery studies are shown in Table 5. The % RSD values for AMB, VAL and HCT were found to be 0.4845, 0.4464 and 0.0551, respectively. The low % RSD values confirm that there is no interference due to the excipients used in formulation. This ensures the accuracy of the method.

Table 5: Recovery studies

Drug	Amount present ( $\mu\text{g/ml}$ )	Amount added ( $\mu\text{g/ml}$ )	Amount found* ( $\mu\text{g/ml}$ )	Amount recovered ( $\mu\text{g/ml}$ )	% Recovery*	S.D	% R.S.D
AMB	1.9872	1.9906	4.0030	2.0158	101.27	0.4879	0.4845
	1.9872	3.9931	5.9954	4.0082	100.43		
	1.9872	5.9896	8.0021	6.0149	100.42		
VAL	31.8496	1.1296	32.9917	1.1421	101.40	0.4508	0.4464
	31.8496	2.0865	33.9588	2.1092	101.08		
	31.8496	3.0587	34.9240	3.0744	100.51		
HCT	5.0068	2.0068	7.0224	2.0156	100.35	0.5503	0.0551
	5.0068	3.9957	8.9933	3.9865	99.77		
	5.0068	6.0025	10.9641	5.9573	99.25		

\*Mean of three observations

From validation, the developed method was found to be simple, rapid, economical, precise, accurate and rugged. Hence the proposed method could be effectively applied for the routine analysis of AMB, VAL and HCT in bulk and in combined tablet dosage form.

#### ACKNOWLEDGEMENT

The authors are thankful to Arulthiru Amma and Thirumathi Amma, Adhiparasakthi charitable medical, educational, cultural trust and Dr. T. Ramesh, M.D., MAPIMS, Melmaruvathur for providing the necessary facilities to carry out the research work. Also thankful to Caplin point, Chennai for supplying the gift samples of AMB, VAL and HCT.

#### REFERENCES

- Budavari S. The Merck Index. 14th ed. Whitehouse Station, NJ, USA: Merck Research Lab, Division of Merck & Co., Inc., 2006.
- Permender Rathee, Sushila Rathee, Shyama Thakur and Vikash Kumar. Simultaneous Estimation of Amlodipine Besylate and Atenolol as A.P.I. and in Tablet Dosage Forms by Vierodt's Method using UV Spectrophotometry. Int J Chem Tech Res 2010; 2 (1): 62 - 68.
- Neela Manish Bhatia, Snehal Jawaharlal Deshmane, Harinath Nivrutti More and Prafulla Balkrishna Choudhari. Simultaneous Spectrophotometric Estimation of the Amlodipine Besylate and Hydrochlorothiazide. Asian J Res Chem 2009; 2 (4): 393 - 397.
- Pallavi Salve, Deepali Garge, Rupali Kirtawade, Pandurang Dhabale and Kishor Burade. Simple Validated Spectroscopic

- Method for Estimation of Amlodipine Besylate from Tablet Formulation. *Asian J Res Chem* 2009; 2 (4): 553 - 555.
5. Priyanka R Patil, Sachin U Rakesh, Dhabale PN and Burade KB. RP - HPLC Method for Simultaneous Estimation of Losartan Potassium and Amlodipine Besylate in Tablet Formulation. *Int J Chem Tech Res* 2009; 1 (3): 464 - 469.
  6. European Pharmacopoeia. 3rd ed. Strasbourg: Council of Europe; 2001.
  7. Dhorda VJ and Shetkar NB. Reversed phase liquid chromatographic determination of Ramipril and Amlodipine in tablets. *Indian Drugs* 1999; 36: 638.
  8. Vaijanath G Dongre, Sweta B Shah, Pravin P Karmuse, Manisha Phadke and Vivek K Jadhav. Simultaneous determination of metoprolol succinate and amlodipine besylate in pharmaceutical dosage form by HPLC. *J Pharm Biomed Anal* 2008; 46 (3): 583 - 586.
  9. Ilango K, Kumar PB and Prasad VRV. Simple and rapid high performance thin layer chromatographic determination of amlodipine in pharmaceutical dosage forms. *Indian J Pharm Sci* 1997; 59 (6): 171 - 173.
  10. Agrekar AP and Powar SG. Simultaneous determination of atenolol and amlodipine in tablets by high performance thin layer chromatography. *J Pharm Biomed Anal* 2000; 21: 1137 - 1142.
  11. Feng Y, Zhang L, Shen Z, Pan F and Zhang Z. Analysis of AML in human plasma by Liquid chromatography - mass spectrometry. *J Chromatogr Sci* 2002; 40 (1): 49 - 53.
  12. Bhatt J, Singh S, Subbaiah G, Shah B, Kambli S and Ameta S. A rapid and sensitive Liquid Chromatography Tandem Mass Spectrometry (LCMS/MS) for the estimation of AML in human plasma. *J Biomed Chromatogr* 2007; 21: 169 - 175.
  13. [www.rxlist.com/exforge-hct-drug.htm](http://www.rxlist.com/exforge-hct-drug.htm).
  14. Goodman and Gillman's. *The Pharmacological Basis of Therapeutics*. 10th ed. New York: McGraw Hill Medical Publishing Division; 2001.
  15. Kocyigit KB, Unsalan S and Rollas S. Determination and validation of Ketoprofen, Pantoprazole and Valsartan together in human plasma by high performance liquid chromatography. *Pharmazie* 2006; 61: 586 - 589.
  16. Daneshalab N, Lewanczuk RZ and Jamali F. Highperformance liquid chromatographic analysis of angiotensin II receptor antagonist Valsartan using a liquid extraction method. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002; 766: 345 - 359.
  17. Gonzalez L, Lopez JA, Alonso RM and Jimenez RM. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high - performance liquid chromatography with fluorimetric detection. *J Chromatogr A* 2002; 949: 49 - 60.
  18. Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R, Nagae Y. and Masuda N. Development and validation of a method for quantitative determination of Valsartan in human plasma by liquid chromatography-tandem mass spectrometry. *J Pharm Biomed Anal* 2007; 43: 1769 - 1774.
  19. Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L and Gu J. A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of Valsartan and Hydrochlorothiazide in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 852: 436 - 442.
  20. Senthamil SP, Gowda VK, Mandal U, Solomon WD and Pal TK. Simultaneous determination of fixed dose combination of Nebivolol and Valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 858: 143 - 150.
  21. Macek J, Klima J and Ptacek P. Rapid determination of Valsartan in human plasma by protein precipitation and highperformance liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci* 2006; 832: 169 - 172.
  22. Hillaert S and Bossche VW. Simultaneous determination of Hydrochlorothiazide and several angiotensin - II - receptor antagonists by capillary electrophoresis. *J Pharm Biomed Anal* 2003; 31: 329 - 339.
  23. Satana E, Altinay S, Goger NG, Ozkan SA and Senturk ZJ. Simultaneous determination of Valsartan and Hydrochlorothiazide in tablets by first - derivative ultraviolet spectrophotometry and LC. *J Pharm Biomed Anal* 2001; 25: 1009 - 1013.
  24. Tatar S and Saglik S. Comparison of UV - and second derivative - spectrophotometric and LC methods for the determination of Valsartan in pharmaceutical formulation. *J Pharm Biomed Anal* 2002; 30: 371 - 375.
  25. Budavari S. *The Merck Index*. 14th ed. Whitehouse Station, NJ, USA: Merck Research Lab, Division of Merck & Co., Inc., 2006.
  26. Baing MM, Vaidya VV, Sane RT, Menon SN and Dalvi K. Simultaneous RP - LC Determination of Losartan Potassium, Ramipril and Hydrochlorothiazide in Pharmaceutical preparations. *Chromatographia* 2006; 64 (5): 293 - 296.
  27. Bhusari KP, Khedekar PB, Seema Dhole and Banode VS. Derivative and Q - analysis spectrophotometric methods for estimation of hydrochlorothiazide and olmesartan medoxomil in tablets. *Indian J Pharm Sci* 2009; 71 (5): 505 - 508.
  28. Daniels SL and Vanderwielen AJ. Stability - Indicating Assay for Hydrochlorothiazide. *J Pharm Sci* 2006; 70 (2): 211 - 215.
  29. Stolarczyk M, masalanka A, Krzek J and Milczarek J. Application of derivative Spectrophotometry for Determination of Enalapril, Hydrochlorothiazide and Valsartan in Complex Pharmaceutical Preparations. *Acta Poloniae Pharm Drug Res* 2008; 65 (3): 275 - 281.
  30. Tian D, Tian X, Tian T, Wang Z and Mo F. Simultaneous determination of Valsartan and hydrochlorothiazide in tablets by RP - HPLC. *Indian J Pharm Sci* 2008; 70 (3): 372 - 374.
  31. Taomin Huang, Zhong He, Bei Yang, Luping Shao, Xiaowei Zheng and Gengli Duan. Simultaneous determination of captopril and hydrochlorothiazide in human plasma by RP - HPLC from linear gradient elution. *J Pharm Biomed Anal* 2006; 41 (2): 644 - 648.
  32. *United States Pharmacopoeia*. 27th ed. Washington DC: United States Pharmacopoeial Convention Inc., 2009.
  33. *Indian Pharmacopoeia*. Vol. II, New Delhi: Govt. of India, Ministry of Health and Family Welfare, Published by the Controller of Publication; 2007.
  34. *British Pharmacopoeia*. Vol. I, London: Her Majesty's Stationary Office; 2009.
  35. ICH: *Proceeding of the International Conference on Harmonisation of Technical Requirement of Registration of Pharmaceuticals for Human Use (ICH Harmonised Tripartite Guidelines)*. Validation of Analytical Procedures: Methodology, Q2B, Geneva, Switzerland: 1996.